Business Insider

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in ...

Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no ...
Nature

Natalizumab-Associated Progressive Multifocal Leukoencephalopathy Risk Stratification

Natalizumab is a high-efficacy monoclonal antibody employed in the treatment of relapsing forms of multiple sclerosis. Its mechanism, which involves blockade of α4-integrin on lymphocytes, strongly ...
Medical Xpress

Virus-specific T cells may predict immunotherapy success for a rare brain infection

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue and often leads to death within a few weeks. It is triggered by human ...
Yahoo Finance

The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
ascopubs.org

Association between rituximab use and progressive multifocal leukoencephalopathy among non-HIV, non-Hodgkin lymphoma Veteran’s Administration patients.

Presence and function of CD14+CD16-HLADRlow monocytes in the peripheral blood of patients with Β-cell non-Hodgkin lymphoma (NHL). Mean age in years at death (sd) 65.1 years (6.9) 67.3 years (6.6) Mean ...